ResMed (RMD)
(Delayed Data from NYSE)
$238.75 USD
-5.37 (-2.20%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $238.78 +0.03 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$238.75 USD
-5.37 (-2.20%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $238.78 +0.03 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth A Momentum A VGM
Zacks News
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ResMed (RMD) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
ResMed's (RMD) solid revenue growth in the first quarter of fiscal 2024 reflects the strength of AirSense 10 and AirSense 11 sleep devices and robust growth in the mask product portfolio.
ResMed (RMD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ResMed (RMD) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 0.61% and 0.51%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ResMed (RMD) Gains From Strong Device Sales Amid Macro Woes
by Zacks Equity Research
ResMed's (RMD) respiratory care business continues to drive growth and the adoption of bilevel and other non-invasive ventilator solutions worldwide.
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) due to the core business' performance and sustained growth in the SaaS business.
ResMed (RMD) Stock Jumps 3.8%: Will It Continue to Soar?
by Zacks Equity Research
ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ResMed (RMD) Gains From Mask Sales Amid Macro Headwinds
by Zacks Equity Research
ResMed's (RMD) respiratory care business continues to drive growth, courtesy of the adoption of bilevel and other non-invasive ventilator solutions worldwide.
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD), backed by the continued demand for digital health solutions.
ResMed's (RMD) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
ResMed (RMD) records a robust sales performance in fiscal Q4 backed by the ongoing combined availability of cloud-connected AirSense 10 and AirSense 11 sleep devices.
Compared to Estimates, ResMed (RMD) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ResMed (RMD) Misses Q4 Earnings Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of -4.19% and 0.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for ResMed (RMD)
by Zacks Equity Research
ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ResMed (RMD) Expands Solutions Portfolio With Somnoware Buyout
by Zacks Equity Research
ResMed (RMD) announces the acquisition of the Somnoware diagnostic management platform.
ResMed's (RMD) New Buyout Aids Growth Amid Rising Costs
by Zacks Equity Research
ResMed's (RMD) respiratory care business witnesses continued customer uptake of bilevel and other non-invasive ventilator solutions worldwide.
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) backed by the continued demand for digital health solutions.
ZBH vs. RMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ZBH vs. RMD: Which Stock Is the Better Value Option?
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ResMed (RMD) reports a solid third-quarter top line, led by strong device sales growth through steady production and delivery of its cloud-connected flow generator devices to meet high market demand.
ResMed (RMD) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 7.01% and 7.95%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Reasons Why You Should Retain ResMed (RMD) Stock For Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) Increased demand for its digital health solution.
EYE vs. RMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EYE vs. RMD: Which Stock Is the Better Value Option?
Reasons Why You Should Retain ResMed (RMD) Stock For Now
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) owing to the increased demand for its sleep and respiratory care devices.
Top Research Reports for Chevron, Novo Nordisk & Amgen
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), Novo Nordisk A/S (NVO) and Amgen Inc. (AMGN).